Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
医学
皮肤病科
大疱性表皮松解症
作者
Shireen V. Guide,Mercedes E. González,Işın Sinem Bağcı,Brittani Agostini,Hubert Chen,Gloria Feeney,Molly Steimer,Binoy Kapadia,Kunju Sridhar,Lori Quesada Sanchez,Franshesca Gonzalez,Matthew Van Ligten,Trevor J. Parry,Surya Chitra,Lisa A. Kammerman,Suma Krishnan,M. Peter Marinkovich
Complete wound healing at 3 and 6 months in patients with dystrophic epidermolysis bullosa was more likely with topical administration of B-VEC than with placebo. Pruritus and mild systemic side effects were observed in patients treated with B-VEC. Longer and larger trials are warranted to determine the durability and side effects of B-VEC for this disease. (Funded by Krystal Biotech; GEM-3 ClinicalTrials.gov number, NCT04491604.).
PDF的下载单位、IP信息已删除
(2025-6-4)
DW
无极微光
cdercder
TE
牧青
Criminology34
Enigma_GEB
Nole
科研狗
学术文献互助
七颗茶香豆
OK
超文献
Kao
渡人舟
罗Eason
xing_xing
秋风
DOC_XIONG
Ali
皖公网安备34019202002308
